How to Cite
Abstract
The efforts to detect specific tumor-associated changes in blood and other biological fluids are by no means new. However, only the development of the most precise modifications of DNA analysis provided real opportunity to monitor tumor behavior in “real time” manner. Two directions should be distinguished within this field of modern oncology: 1) the early detection of cancer in apparently healthy individuals; 2) the use of liquid biopsy in patients with confirmed cancer diagnosis for a broad range of applications, such as the early diagnosis of recurrence or monitoring the treatment efficacy.
It should be stated, that the first direction of the research has not yet led to the results suitable for implementation in real world practice. Nevertheless, there are staggering technological advances in the analytical performance of NGS-based methods, which are applied to this task. The emerging non-standard approaches, involving the use of recently discovered peculiarities of the ctDNA fragmentation in plasma, or the complex approaches, utilizing a number of diverse methods simultaneously, are of great interest. The second, less ambitious direction of liquid biopsy studies is much closer to clinical use. This approach has already been widely used for such an actual issue, as the early non-invasive T790M detection in plasma of metastatic lung cancer patients, undergoing anti-EGFR therapy. Aside from the practical advances, the studies of various aspects of liquid biopsy provide all sorts of invaluable scientific information, for example regarding the precise timing patterns of the emergence of the resistance to anticancer drugs and the dynamics of its regression after changing of therapy regimen.
References
Perakis S., Speicher M.R. Emerging concepts in liquid biopsies. BMC Med. 2017; 15(1): 75.
Junqueira-Neto S., Batista I.A., Costa J.L. et al. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA. Acta Cytol. 2019; 63(6):479‐488.
Booth S.N., King J.P., Leonard J.C. et al. Serum carcinoembryonic antigen in clinical disorders. Gut. 1973;14(10):794-799.
Buamah P.K., Bent D.J., Bodger W.A. et al. A profile of serum CA 15-3, carcinoembryonic antigen, alkaline phosphatase, and gamma-glutamyl transferase levels in patients with breast cancer. J Surg Oncol. 1993; 53:84-87.
Kim M.Y., Oskarsson T., Acharyya S. et al. Tumor self-seeding by circulating cancer cells. Cell. 2009; 139(7):1315-1326.
Thierry A.R., El Messaoudi S., Gahan P.B. et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016; 35: 347-376.
Diehl F., Li M., Dressman D. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-16373.
Jiang P., Lo Y.M.D. The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics. Trends Genet. 2016; 32: 360–371.
Mouliere F., Chandrananda D., Piskorz A.M. et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466): pii: eaat4921.
Snyder M.W., Kircher M., Hill A.J. et al. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016; 164: 57-68.
Hellwig S., Nix D.A., Gligorich K.M. et al. Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. PLoS One. 2018; 13(7).
Liu X., Lang J., Li S. et al. Fragment Enrichment of Circulating Tumor DNA With Low-Frequency Mutations. Front Genet. 2020;11: 147.
Yao W., Mei C., Nan X. et al. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study. Gene. 2016; 590(1):142-148.
Diehl F., Schmidt K., Choti M.A. et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–90.
Alekseeva L.A., Mironova N.L., Brenner E.V. et al. Alteration of the exDNA profile in blood serum of LLC-bearing mice under the decrease of tumour invasion potential by bovine pancreatic DNase I treatment. PLoS One. 2017; 12(2): e0171988.
Bronkhorst A.J., Ungerer V., Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019; 17: 100087.
Chelobanov B.P., Laktionov P.P., Vlasov V.V. Proteins involved in binding and cellular uptake of nucleic acids. Biochemistry (Mosc). 2006; 71: 583-96.
Vlassov V.V., Laktionov P.P., Rykova E.Y. Extracellular nucleic acids. Bioessays. 2007; 29(7):654-667.
Khier S., Lohan L. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future Sci OA. 2018; 23(4): FSO295.
Mouliere F., El Messaoudi S., Gongora C. et al. Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Transl Oncol. 2013; 6(3):19-28.
Aravanis A.M., Lee M., Klausner R.D. Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection. Cell. 2017; 168(4):571-574.
Phallen J., Sausen M., Adleff V. et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017; 9: pii: eaan2415.
Wu X., Li J., Gassa A. et al. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Int J Biol Sci. 2020; 16(9):1551-1562.
Newman A.M., Bratman S.V., To J. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20(5):548-554.
Newman A.M., Lovejoy A.F., Klass D.M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016; 34: 547-555.
Shen S.Y., Singhania R., Fehringer G. et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018; 563(7732):579-583.
Locke W.J., Guanzon D., Ma C. et al. DNA Methylation Cancer Biomarkers: Translation to the Clinic. Front Genet. 2019;10: 1150.
Kaiser J. 'Liquid biopsy' for cancer promises early detection. Science. 2018;359(6373):259.
Lam W.K.J., Chan K.C.A. Plasma DNA for early cancer detection - opportunities and challenges. Expert Rev Mol Diagn. 2019; 19: 5-7.
Cohen J.D., Li L., Wang Y. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018; 359: 926-930.
Cristiano S., Leal A., Phallen J. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019; 570(7761):385-389.
Ulz P., Perakis S., Zhou Q. et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nat Commun. 2019; 10(1):4666.
Douville C., Cohen J.D., Ptak J. et al. Assessing aneuploidy with repetitive element sequencing. Proc Natl Acad Sci U S A. 2020; 117(9):4858-4863.
Razavi P., Li B.T., Brown D.N. et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019; 25: 1928-1937.
Bettegowda C., Sausen M., Leary R.J. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6: 224ra224.
Lebofsky R., Decraene C., Bernard V. et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol. 2015; 9(4):783-790.
Garcia-Murillas I., Chopra N., Comino-Méndez I. et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019.
O'Leary B., Hrebien S., Beaney M. et al. Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clin Chem. 2019; 65(11):1405-1413.
Coombes R.C., Page K., Salari R. et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res. 2019; 25(14):4255-4263.
Parsons H.A., Rhoades J., Reed S.C. et al. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020.
Tie J., Cohen J.D., Wang Y. et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. 2019;8(4):663-671.
Reinert T., Henriksen T.V., Christensen E. et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019.
Ou S.I., Nagasaka M., Zhu V.W. Liquid Biopsy to Identify Actionable Genomic Alterations. Am Soc Clin Oncol Educ Book. 2018; 38: 978-997.
Galot R., van Marcke C., Helaers R. et al. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2020;104: 104631.
Thierry A.R., Mouliere F., El Messaoudi S. et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014; 20(4): 430-435.
Fiala C., Diamandis E.P. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018; 16: 166.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021